Navigation Links
Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
Date:9/22/2008

Common Genetic Variations Predict Patient Response to Novel Beta Blocker

Therapy

TORONTO, Sept. 22 /PRNewswire/ -- Bucindolol, an investigational, pharmacologically unique beta-blocker and mild vasodilator, significantly reduces hospitalization and death among heart failure patients with very favorable genotypes, according to results of a large DNA study presented today as a poster at the annual meeting of the Heart Failure Society of America. Researchers found that common genetic variations can predict which heart failure patients will have the greatest therapeutic response to bucindolol.

ARCA biopharma has submitted a New Drug Application (NDA) for bucindolol to the U.S. Food and Drug Administration for the treatment of chronic heart failure.

"The ability to predict patient response to bucindolol makes it easier for physicians to match the right patient to the right medicine, potentially avoiding months of trial-and-error therapy and helping very sick heart failure patients achieve better outcomes sooner," said Christopher O'Connor, M.D., Director of the Heart Center at Duke University Medical Center and presenter of the study. "This data brings us much closer to realizing the benefits of personalized medicine in heart failure."

The prospectively-designed DNA sub-study included more than 1,000 patients enrolled in the Beta-Blocker Evaluation of Survival Trial (BEST), the largest heart failure mortality trial conducted primarily in the United States. Researchers evaluated therapeutic response to bucindolol among patients with genetic variations, or polymorphisms, in two adrenergic receptors that help regulate cardiac function: beta 1 389 Arg/Gly and alpha 2c 322-325 WT/Del. Researchers identified three distinct genotypes that predict the effect of bucindolol: very favorable (47% of BEST patients), favorable (40%) and unfavorable (13%).

In the study, patients with the very favorable genotype
'/>"/>

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
2. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
3. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
4. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
9. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
10. On the boil: New nano technique significantly boosts boiling efficiency
11. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... Optimal Research, LLC has been nominated as ... "Best Clinical Site or Trial Network". This ... selected as a nominee in this ViE award category ... distinction in 2014. The ViE awards were created to ... positive contributions of companies and individuals in the vaccine ...
(Date:3/25/2015)... 25, 2015 Laboratory workers can ... and Analytical Balances to get best-performing features while ... weighing balances from the trusted brand include: , ... increase your efficiency by providing a large weighing ... Weighing modes include parts counting, percent weighing, checkweighing, ...
(Date:3/25/2015)... 2015 An increase of awareness related ... forms of food nutrients, regulatory changes and concerns related ... in demand for natural astaxanthin over the past few ... up their capacities to satisfy the rising demand. ... source astaxanthin (used in nutraceuticals, aqua feed, food and ...
(Date:3/25/2015)... IL (PRWEB) March 25, 2015 Having ... in the latter part of 2014, ITRA Global proudly ... Global, the International Tenant Representative Alliance, based in the ... to representing tenants and occupiers of commercial real estate. ... estate advisory firm in Poland that exclusively advises occupiers ...
Breaking Biology Technology:Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2International Organization Expands its Global Reach to Warsaw, Poland 2
... SAN DIEGO, Aug. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ... call on Wednesday, August 12, 2009 at 1:30 p.m. Pacific (4:30 ... provide an update on its business. , , ... by dialing (866) 305-6438 for domestic callers, or (706) 679-7161 for ...
... CARLISLE, Mass., Aug. 5 CapitalBio Corporation and ... fully integrated microarray solution platform. CapitalBio Corp., a ... microarray instrument systems, in collaboration with VigeneTech, developers ... now offers a platform that combines the superior ...
... , , , ... Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged ... human viral diseases, today announced the pricing of an underwritten offering ... $3.14 per share. After underwriting discounts and commissions and estimated offering ...
Cached Biology Technology:CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform 2CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform 3Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock 2
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/17/2015)... 17, 2015  MecklerMedia Corporation (OTCQX: MECK) announced ... service robots ever held in New ... May 11-13, 2015 at the Javits Convention Center. ... event include: Acorn Product Development; Axis NJ; c-Link ... Robotics; Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... deficit/hyperactivity disorder, ADHD, is one of the most ... children are affected with the disorder. Key symptoms ... and/or a reduced ability to focus attention. Clinically, ... inattentive subtype, a primarily hyperactive/impulsive subtype, and a ...
... research has found that children raised in homes without ... in traditional nuclear families. Now a new study that ... this is so challenges a popular explanation of the ... live in homes without fathers have sex earlier are ...
... In two separate studies, a major component ... to help prolong the preservation of both stored ... the current double issue of Cell Transplantation ... http://www.ingentaconnect.com/content/cog/ct , devoted to organ preservation and transplantation ...
Cached Biology News:The role of genetic factors in adult ADHD 2The role of genetic factors in adult ADHD 3The role of genetic factors in adult ADHD 4The role of genetic factors in adult ADHD 5The role of genetic factors in adult ADHD 6Genes may explain why children who live without dads have earlier sex 2Green tea component may help preserve stored platelets, tissues 2Green tea component may help preserve stored platelets, tissues 3
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Request Info...
... Inventory Storage Racks for Standard 3" ... fit all makes and models of ... of high quality stainless steel and ... stainless steel or plastic boxes. ...
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: